4hw.com.cn: in August 2017, Erkang Pharmaceutical (300267. SZ), once regarded as one of the representatives of A-share high growth enterprises, received the notice of investigation from CSRC due to suspected violation of securities laws and regulations. On April 18, 2018, Hunan securities regulatory bureau of China Securities Regulatory Commission issued the notice of administrative penalty in advance on Erkang pharmaceutical, which made corresponding administrative penalty on the case of Erkang pharmaceutical suspected of information disclosure violation.
In 2015, Erkang Pharmaceutical Co., Ltd. was suspected of falsely increasing its operating revenue by 18.0588 million yuan and its profit by 15.86 million yuan, accounting for 1.03% of the operating revenue and 2.62% of the net profit disclosed in the current consolidated statement; in 2016, it was more serious, suspected of falsely increasing its operating revenue by 255 million yuan and its net profit by 232 million yuan, accounting for 8.61% and 22.63% of the net profit disclosed in the current consolidated statement.
In response to this situation, Hunan securities regulatory bureau has imposed different degrees of penalties on Erkang pharmaceutical and its relevant executives, including ordering Erkang pharmaceutical to make corrections, giving a warning, and imposing a fine of 600000 yuan; giving a warning to the directly responsible executives, and imposing a fine of 300000 yuan; and imposing a fine of 30000-100000 yuan on other responsible personnel, and giving a warning.
According to the reporter, at present, many lawyers have launched investor claim lawsuit against the false disclosure of Erkang pharmaceutical. After resumption of trading in November 2017, Erkang pharmaceutical first went through four consecutive trading stops, and then the stock price fluctuated repeatedly. As of the afternoon of April 19, 2018, Erkang pharmaceutical reported 7.37 yuan / share, up 1.66%. On March 16, the Shenzhen Stock Exchange issued an inquiry letter on the recent transaction of Erkang pharmaceutical, but the share price of Erkang pharmaceutical still rose 5.82% throughout the day in the next transaction.